A Hierarchical Network of Interreceptor Interactions Determines Signal Transduction by Neu Differentiation Factor/Neuregulin and Epidermal Growth Factor

REFERENCES

• Alimandi, M., A. Romano, M. C. Curia, R. Muraro, P. Fedi, S. A. Aaronson, P. P. Di Fiore, and M. H. Kraus. 1995. Cooperative signaling of ErbB-3 and ErbB-2 in neoplastic transformation and human mammary carcinoma cells. Oncogene 10: 1813–1821.
   PubMed Web of Science ®Google Scholar
• Bargmann, C. I., and R. A. Weinberg. 1988. Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene. Proc. Natl. Acad. Sci. USA 85: 5394–5398.
   PubMed Web of Science ®Google Scholar
• Beerli, R. R., W. Wels, and N. E. Hynes. 1994. Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J. Biol. Chem. 269: 23931–23936.
   PubMed Web of Science ®Google Scholar
• Ben-Levy, R., E. Peles, R. Goldman-Michael, and Y. Yarden. 1992. An oncogenic point mutation confers high affinity ligand binding to the neu receptor. J. Biol. Chem. 267: 1730–17313.
   Google Scholar
• Blechman, J. M., S. Lev, J. Barg, M. Eisenstein, B. Vaks, Z. Vogel, D. Givol, and Y. Yarden. 1995. The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction. Cell 80: 103–113.
   PubMed Web of Science ®Google Scholar
• Cao, H., L. Bangalore, B. J. Bormann, and D. F. Stern. 1992. A subdomain in the transmembrane domain is necessary for p185neu activation. EMBO J. 11: 923–932.
   PubMed Web of Science ®Google Scholar
• Carraway, K. L., and L. C. Cantley. 1994. A neu acquaintance for ErbB3 and ErbB4: a role for receptor heterodimerization in growth signaling. Cell 78: 5–8.
   PubMed Web of Science ®Google Scholar
• Carraway, K. L., M. X. Sliwkowski, R. Akita, J. V. Platko, P. M. Guy, A. Nuijens, A. J. Diamonti, R. L. Vandlen, L. C. Cantley, and R. A. Cerione. 1994. The erbB3 gene product is a receptor for heregulin. J. Biol. Chem. 269: 14303–14306.
   PubMed Web of Science ®Google Scholar
• Carraway, K. L., S. P. Soltoff, A. J. Diamonti, and L. C. Cantley. 1995. Heregulin stimulates mitogenesis and phosphatidylinositol 3-kinase in mouse fibroblasts transfected with erbB2/neu and erbB3. J. Biol. Chem. 270: 7111–7116.
   PubMed Web of Science ®Google Scholar
• Chen, X., G. Levkowitz, E. Tzahar, D. Karunagaran, S. Lavi, N. Ben-Baruch, O. Leitner, B. Ratzkin, S. S. Bacus, and Y. Yarden. 1996. An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4. J. Biol. Chem. 271: 7620–7629.
   PubMed Web of Science ®Google Scholar
• Cohen, B., J. M. Green, L. Foy, and P. H. Fell. 1996. HER4-mediated biological and biochemical properties in NIH 3T3 cells. J. Biol. Chem. 271: 4813–4818.
   PubMedGoogle Scholar
• Dougall, W. C., X. Qian, N. C. Peterson, M. J. Miller, A. Samanta, and M. Greene. 1994. The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 9: 2109–2123.
   PubMed Web of Science ®Google Scholar
• Evan, G. I., G. K. Lewis, G. Ramsay, and J. M. Bishop. 1985. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol. Cell. Biol. 5: 3610–3616.
   PubMed Web of Science ®Google Scholar
• Fantl, W. J., D. E. Johnson, and L. T. Williams. 1993. Signalling by receptor tyrosine kinases. Annu. Rev. Biochem. 62: 453–481.
   PubMed Web of Science ®Google Scholar
• Goldman, R., R. Ben-Levy, E. Peles, and Y. Yarden. 1990. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry 29: 11024–11028.
   PubMed Web of Science ®Google Scholar
• Graus-Porta, D., R. R. Beerli, and N. E. Hynes. 1995. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol. Cell. Biol. 15: 1182–1191.
   PubMed Web of Science ®Google Scholar
• Gullick, W. J. 1994. A new model for the interaction of EGF-like ligands with their receptors: the new one-two. Eur. J. Cancer 30A: 2186.
   PubMedGoogle Scholar
• Gullick, W. J., M. S. Berger, P. L. Bennett, J. B. Rothbard, and M. D. Waterfield. 1987. Expression of the c-erbB-2 protein in normal and transformed cells. Int. J. Cancer. 40: 246–254.
   PubMed Web of Science ®Google Scholar
• Guy, P. M., J. V. Platko, L. C. Cantley, R. A. Cerione, and K. L. Carraway. 1994. Insect cell-expressed p180ErbB3 possesses an impaired tyrosine kinase activity. Proc. Natl. Acad. Sci. USA 91: 8132–8136.
   PubMed Web of Science ®Google Scholar
• Hammacher, A., K. Mellstrom, C.-H. Heldin, and B. Westermark. 1989. Isoform-specific induction of actin reorganization by platelet-derived growth factor suggests that the functionally active receptor is a dimer. EMBO J. 8: 2489–2495.
   PubMed Web of Science ®Google Scholar
• Hynes, N. E., and D. F. Stern. 1994. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta 1198: 165–184.
   PubMed Web of Science ®Google Scholar
• Karunagaran, D., E. Tzahar, R. R. Beerli, X. Chen, D. Graus-Porta, B. Ratzkin, R. Seger, N. E. Hynes, and Y. Yarden. 1996. ErbB-2 is a common signaling subunit of NDF- and EGF-receptors: implications for breast cancer. EMBO J. 15: 254–264.
   PubMed Web of Science ®Google Scholar
• Karunagaran, D., E. Tzahar, N. Liu, D. Wen, and Y. Yarden. 1995. Neu differentiation factor inhibits EGF binding: a model for trans-regulation within the ErbB family of receptor tyrosine kinases. J. Biol. Chem. 270: 9982–9990.
   PubMedGoogle Scholar
• Kim, H.-H., S. L. Sierke, and J. G. Koland. 1994. Epidermal growth factor-dependent association of phosphatidylinositol 3′ -kinase with the erbB-3 gene product. J. Biol. Chem. 269: 24747–24755.
   PubMed Web of Science ®Google Scholar
• King, C. R., I. Borrello, F. Bellot, P. Comoglio, and J. Schlessinger. 1988. EGF binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SKBR-3. EMBO J. 7: 1647–1651.
   PubMed Web of Science ®Google Scholar
• King, C. R., M. H. Kraus, and S. A. Aaronson. 1985. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229: 974–976.
   PubMed Web of Science ®Google Scholar
• Kita, Y. A., J. Braff, Y. Luo, D. Wen, D. Brankow, S. Hu, S. A. Prigent, W. J. Gullick, and M. Nicolson. 1994. NDF/heregulin stimulates the phosphorylation of HER3/erbB3. FEBS Lett. 349: 139–143.
   PubMedGoogle Scholar
• Koch, A. C., D. Anderson, M. F. Moran, C. Ellis, and T. Pawson. 1991. SH-2 and SH-3 domains: elements that control interactions of cytoplasmic signaling proteins. Science 252: 668–674.
   PubMed Web of Science ®Google Scholar
• Kokai, Y., J. N. Myers, T. Wada, V. I. Brown, C. M. LeVea, J. G. Davis, K. Dobashi, and M. I. Greene. 1989. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 58: 287–292.
   PubMed Web of Science ®Google Scholar
• Lee, J., T. J. Dull, I. Lax, J. Schlessinger, and A. Ullrich. 1989. HER-2 cytoplasmic domain generates normal mitogenic and transforming signals in a chimeric receptor. EMBO J. 8: 167–173.
   PubMed Web of Science ®Google Scholar
• Lehvaslaiho, H., L. Lehtola, L. Sistonen, and K. Alitalo. 1989. A chimeric EGF-R-neu proto-oncogene allows EGF to regulate neu tyrosine kinase and cell transformation. EMBO J. 8: 159–166.
   PubMedGoogle Scholar
• Lonardo, F., E. Di Marco, C. R. King, J. H. Pierce, O. Segatto, S. A. Aaronson, and P. P. Di Fiore. 1990. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. New Biol. 2: 992–1003.
   PubMedGoogle Scholar
• Marikovsky, M., S. Lavi, R. Pinkas-Kramarski, D. Karunagaran, N. Liu, D. Wen, and Y. Yarden. 1995. ErbB-3 mediates differential mitogenic effects of NDF/heregulin isoforms on mouse keratinocytes. Oncogene 10: 1403–1411.
   PubMedGoogle Scholar
• Massagué, J. 1990. Transforming growth factor-α: a model for membrane anchored growth factors. J. Biol. Chem. 265: 21393–21396.
   PubMed Web of Science ®Google Scholar
• Miller, A. D., and G. J. Rosman. 1989. Improved retroviral vectors for gene transfer and expression. BioTechniqes 7: 980–990.
   Google Scholar
• Munson, P. J., and D. Rodbard. 1980. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 107: 220–239.
   PubMed Web of Science ®Google Scholar
• Park, J. G., H. Frucht, R. V. LaRocca, D. P. J. Bliss, Y. Kurita, T.-R. Chen, J. G. Henslee, J. B. Trepel, R. T. Jensen, B. E. Johnson, Y. J. Bang, J.-P. Kim, and A. F. Gazdar. 1990. Characteristics of cell lines established from human gastric carcinoma. Cancer Res. 50: 2773–2780.
   PubMedGoogle Scholar
• Pawson, T., and J. Schlessinger. 1993. SH2 and SH3 domains. Curr. Biol. 3: 434–442.
   PubMed Web of Science ®Google Scholar
• Peles, E., R. Ben-Levy, E. Or, A. Ullrich, and Y. Yarden. 1991. Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase Cγ. EMBO J. 10: 2077–2086.
   PubMed Web of Science ®Google Scholar
• Peles, E., R. Ben-Levy, E. Tzahar, L. Naili, D. Wen, and Y. Yarden. 1993. Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2. EMBO J. 12: 961–971.
   PubMedGoogle Scholar
• Peles, E., and Y. Yarden. 1993. Neu and its ligands: from an oncogene to neural factors. Bioessays 15: 815–824.
   PubMed Web of Science ®Google Scholar
• Plowman, G. D., J. M. Green, J.-M. Culouscou, G. W. Carlton, V. M. Rothwell, and B. Sharon. 1993. Heregulin induces tyrosine phosphorylation of HER4/p180erbB-4. Nature (London) 366: 473–475.
   PubMed Web of Science ®Google Scholar
• Prigent, S. A., and N. R. Lemoine. 1992. The type I (EGFR-related) family of growth factor receptors and their ligands. Proc. Growth Factor Res. 4: 1–24.
   PubMedGoogle Scholar
• Riese, D. J., T. M. van Raaij, G. D. Plowman, G. C. Andrews, and D. F. Stern. 1995. The cellular response to neuregulins is governed by complex interactions of the ErbB receptor family. Mol. Cell. Biol. 15: 5770–5776.
   PubMed Web of Science ®Google Scholar
• Slamon, D. J., G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182.
   PubMed Web of Science ®Google Scholar
• Slamon, D. J., W. Godolphin, L. A. Jones, J. A. Holt, S. G. Wong, D. E. Keith, W. J. Levin, S. G. Stuart, J. Udove, A. Ullrich, and M. F. Press. 1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712.
   PubMed Web of Science ®Google Scholar
• Sliwkowski, M. X., G. Schaefer, R. W. Akita, J. A. Lofgren, V. D. Fitzpatrick, A. Nuijens, B. M. Fendly, R. A. Cerione, R. L. Vandlen, and K. L. Carraway. 1994. Coexpression of erbB2 and erbB-3 proteins reconstitutes a high affinity receptor for heregulin. J. Biol. Chem. 269: 14661–14665.
   PubMed Web of Science ®Google Scholar
• Soltoff, S. P., K. L. Carraway, S. A. Prigent, W. G. Gullick, and L. C. Cantley. 1994. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol. Cell. Biol. 14: 3550–3558.
   PubMed Web of Science ®Google Scholar
• Soos, M. A., J. Whittaker, R. Lammers, A. Ullrich, and K. Siddle. 1990. Receptors for insulin and insulin-like growth factor 1 form hybrid dimers. Biochem. J. 270: 383–390.
   PubMed Web of Science ®Google Scholar
• Stancovski, I., E. Hurwitz, O. Leitner, A. Ullrich, Y. Yarden, and M. Sela. 1991. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB-2 receptor on tumor growth. Proc. Natl. Acad. Sci. USA 88: 8691–8695.
   PubMed Web of Science ®Google Scholar
• Stancovski, I., M. Sela, and Y. Yarden. 1994. Molecular and clinical aspects of the Neu/ErbB-2 receptor tyrosine kinase, p. 161–191. In M. Lippman and R. Dikson (ed.), Regulatory mechanisms of breast cancer. Kluwer Academic Publishers, Boston.
   Google Scholar
• Stern, D. F., and M. P. Kamps. 1988. EGF-stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions. EMBO J. 7: 995–1001.
   PubMed Web of Science ®Google Scholar
• Sternberg, M. J., and W. J. Gullick. 1990. A sequence motif in the transmembrane region of growth factor receptors with tyrosine kinase activity mediates dimerization. Protein Eng. 3: 245–248.
   PubMedGoogle Scholar
• Tzahar, E., G. Levkowitz, D. Karunagaran, L. Yi, E. Peles, S. Lavi, D. Chang, N. Liu, A. Yayon, D. Wen, and Y. Yarden. 1994. ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all NDF/heregulin iso-forms. J. Biol. Chem. 269: 25226–25233.
   PubMed Web of Science ®Google Scholar
• van der Geer, P., T. Hunter, and R. A. Lindberg. 1994. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu. Rev. Cell Biol. 10: 251–337.
   PubMedGoogle Scholar
• Wada, T., X. Qian, and M. I. Greene. 1990. Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell 61: 1339–1347.
   PubMed Web of Science ®Google Scholar
• Wallasch, C., F. U. Weiss, G. Niederfellner, B. Jallal, W. Issing, and A. Ullrich. 1995. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J. 14: 4267–4275.
   PubMed Web of Science ®Google Scholar
• Weiner, D. B., J. Liu, J. A. Cohen, W. V. Williams, and M. I. Greene. 1989. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature (London) 339: 230–231.
   PubMed Web of Science ®Google Scholar
• Wen, D., S. V. Suggs, D. Karunagaran, N. Liu, R. L. Cupples, Y. Luo, A. M. Jansen, N. Ben-Baruch, D. B. Trollinger, V. L. Jacobson, T. Meng, H. S. Lu, S. Hu, D. Chang, D. Yanigahara, R. A. Koski, and Y. Yarden. 1994. Structural and functional aspects of the multiplicity of Neu differentiation factors. Mol. Cell. Biol. 14: 1909–1919.
   PubMedGoogle Scholar
• Yarden, Y. 1990. Agonistic antibodies stimulate the kinase encoded by the neu proto-oncogene in living cells but the oncogenic mutant is constitutively active. Proc. Natl. Acad. Sci. USA 87: 2569–2573.
   PubMed Web of Science ®Google Scholar
• Yarden, Y., and J. Schlessinger. 1987. Epidermal growth factor induce rapid, reversible aggregation of purified epidermal growth factor receptor. Biochemistry 26: 1443–1445.
   PubMed Web of Science ®Google Scholar
• Yarden, Y., and A. Ullrich. 1988. Growth factor receptor tyrosine kinases. Annu. Rev. Biochem. 57: 443–478.
   PubMed Web of Science ®Google Scholar